Skip to main content
SpringerLink
Log in

Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment

  • Original Articles
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Patients with Graves’ thyrotoxicosis lose weight despite increased appetite and food intake, thus suggesting a disturbed balance between energy intake and expenditure. Underlying mechanisms are not fully elucidated. The objective of this study was to investigate whether hormonal factors, known to affect hunger/satiety, change significantly over time as pharmacological treatment turns hyperthyroidism into euthyroidism. For that purpose 11 patients with Graves’ thyrotoxicosis were given thiamazole and I-thyroxine for 18–20 mo. They were investigated on three occasions: Test 1: before pharmacological therapy; Test 2: during medication; Test 3: a few months after conclusion of the pharmacological treatment. Sixteen healthy subjects were also investigated for comparison. The participants were fasted overnight. Blood samples for determination of plasma glucose and serum concentrations of free T3 and T4, TSH, albumin, cortisol, insulin, GH, IGF-1, IGFBP-1, leptin, and ghrelin were drawn in the morning from an antecubital vein. Laboratory data obtained in test 1 were statistically compared with those in tests 2 and 3. The study showed that the free T3 level declined from 42.8±4.3 pmol/L in test 1 to 6.0±0.8 pmol/L in test 2 (85±2% decline), and 5.5±0.3 pmol/L in test 3 (86±2% decline). The free T4 level fell concomitantly from 65.2±4.8 to 16.6±1.7 and 14.4±1.2 pmol/L. The glucose level was significantly higher during hyperthyroidism (test 1) than during euthyroidism (tests 2 and 3), whereas cortisol, insulin, GH, IGF-1, and leptin levels were similar. The IGFBP-1 level was initially high (48.8±8.5 µg/L in test 1), but with a relative decline in free T3 of 85±2% (test 2) the IGFBP-1 level declined by 34±13%, and with a free T3 decline of 86±2% (test 3) the binding protein fell by 39±29%. This brought about increased IGF-1 bioavailability as reflected by a rising IGF-1/IGFBP-1 ratio from 5.1±1.1 to 13.8±2.9 (p<0.01). The ghrelin level was low (2454±304 ng/L) in test 1. It increased to 3127±397 ng/L in test 2 (p<0.05), and to 3348±279 ng/L in test 3 (p<0.01). Conclusion: Both ghrelin secretion and IGF-1 bioavailability are low in patients with untreated thyrotoxicosis, but increase markedly as pharmacotherapy makes them euthyroid. These metabolic changes may be caused by the transition of hyperthyroidism into euthyroidism rather than by the pharmacotherapy per se, since the metabolic changes prevailed also in the posttreatment period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ingbar, S. H. (1985). In: Textbook of endocrinology. Wilson, J. D. and Foster, D. W. (eds.). Saunders: Philadelphia, PA.

    Google Scholar 

  2. Havel, P. J. (2001). Exp. Biol. Med. 226, 963–977.

    CAS  Google Scholar 

  3. Weigle, D. S., Bukowski, T., Foster, D., et al. (1995). J. Clin. Invest. 96, 2065–2070.

    PubMed  CAS  Google Scholar 

  4. Rink, T. J. (1995). Nature 372, 406–407.

    Article  Google Scholar 

  5. Romon, M., Lebel, P., Velly, C., Marecaux, N., Fruchart, J. C., and Dallongeville, J. (1999). Am. J. Physiol. 277, E855-E861.

    PubMed  CAS  Google Scholar 

  6. Stephens, T. W., Basinski, M., Bristow, P. K., et al. (1995). Nature 377, 530–532.

    Article  PubMed  CAS  Google Scholar 

  7. Rohner-Jeanrenaud, F. and Jeanrenaud, B. (1996). N. Engl. J. Med. 334, 324–325.

    Article  PubMed  CAS  Google Scholar 

  8. Flood, J. F. and Morley, J. E. (1991). Peptides 12, 1329–1332.

    Article  PubMed  CAS  Google Scholar 

  9. Boden, G., Cheu, X., Kolaczynski, J. W., and Polansky, M. (1997). J. Clin. Invest. 100, 1107–1113.

    PubMed  CAS  Google Scholar 

  10. Elimam, A., Knutsson, U., Brönnegård, M., Stierna, P., Albertsson-Wikland, K., and Marcus, C. (1998). Eur. J. Endocrinol. 139, 615–620.

    Article  PubMed  CAS  Google Scholar 

  11. Nakazato, M., Murakami, N., Date, Y., et al. (2001). Nature 409, 194–198.

    Article  PubMed  CAS  Google Scholar 

  12. Wren, A. M., Seal, L. J., Cohen, M. A., et al. (2001). J. Clin. Endocrinol. Metab. 86, 5992–5995.

    Article  PubMed  CAS  Google Scholar 

  13. Shintani, M., Ogawa, Y., Ebihara, K., et al. (2001). Diabetes 50, 227–232.

    Article  PubMed  CAS  Google Scholar 

  14. Otto, B., Cuntz, U., Fruehauf, E., et al. (2001). Eur. J. Endocrinol. 145, 669–673.

    Article  PubMed  CAS  Google Scholar 

  15. Tschöp, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., and Heiman, M. L. (2001). Diabetes 50, 707–709.

    Article  PubMed  Google Scholar 

  16. Riis, A. L. D., Hansen, T. K., Møller, N., Weeke, J., and Jørgensen, J. O. L. (2003). J. Clin. Endocrinol. Metab. 88, 853–857.

    Article  PubMed  CAS  Google Scholar 

  17. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999). Nature 402, 656–660.

    Article  PubMed  CAS  Google Scholar 

  18. Maffei, M., Halaas, J., Ravussin, E., et al. (1995). Nat. Med. 1, 1155–1161.

    Article  PubMed  CAS  Google Scholar 

  19. Considine, R. V., Sinha, M. K., Heiman, M. L., et al. (1996). N. Engl. J. Med. 334, 292–295.

    Article  PubMed  CAS  Google Scholar 

  20. Grinspoon, S., Gulick, T., Askari, H., et al. (1996). J. Clin. Endocrinol. Metab. 81, 3861–3863.

    Article  PubMed  CAS  Google Scholar 

  21. Valcavi, R., Zini, M., Peino, R., Casanueva, F. F., and Dieguez, C. (1997). J. Clin. Endocrinol. Metab. 82, 632–634.

    Article  Google Scholar 

  22. Mantzoros, C. S., Rosen, H. N., Greenspan, S. L., Flier, J. S., and Moses, A. C. (1997). J. Clin. Endocrinol. Metab. 82, 497–499.

    Article  PubMed  CAS  Google Scholar 

  23. Yaturu, S., Prado, S., and Grimes, S. R. (2004). J. Cell Biochem. 93, 491–496.

    Article  PubMed  CAS  Google Scholar 

  24. Nogueiras, R., Gualillo, O., Caminos, J. E., Casanueva, F. F., and Dieguez, C. (2003). Obes. Res. 11, 408–414.

    Article  PubMed  CAS  Google Scholar 

  25. Iglesias, P., Alvarez Fidalgo, P., Codoceo, R., and Diez, J. J. (2003). Clin. Endocrinol. (Oxf.) 59, 621–629.

    Article  CAS  Google Scholar 

  26. Sanfini, F., Marsili, A., Mammoli, C., et al. (2004). J. Endocrinol. Invest. 27, RC5–7.

    Google Scholar 

  27. Schultes, B., Oltmanns, K. M., Kern, W., Fehm, H. L., Born, J., and Peters, A. (2003). J. Clin. Endocrinol. Metab. 88, 1133–1141.

    Article  PubMed  CAS  Google Scholar 

  28. Lee, P. D. K., Conover, C. A., and Powell, D. R. (1993). Proc. Soc. Exp. Biol. Med. 204, 4–29.

    PubMed  CAS  Google Scholar 

  29. Guler, H.-P., Zapf, J., and Froesch, E. R. (1987). N. Engl. J. Med. 317, 137–140.

    Article  PubMed  CAS  Google Scholar 

  30. Röjdmark, S., Rydvald, Y., Aquilonius, A., and Brismar, K. (2000). Clin. Endocrinol. 52, 313–318.

    Article  Google Scholar 

  31. Amino, N., Yabu, Y., Miki, T., et al. (1981). J. Clin. Endocrinol. Metab. 53, 113–116.

    Article  PubMed  CAS  Google Scholar 

  32. Bannai, C., Yamashita, K., Kugai, N., Koide, Y., and Akisada, M. (1985). Horm. Metab. Res. 17, 671–673.

    PubMed  CAS  Google Scholar 

  33. Colebunders, R., Bourdoux, P., Beckaert, J., Mahler, C., and Parizel, G. (1984). J. Endocrinol. Invest. 7, 379–381.

    PubMed  CAS  Google Scholar 

  34. Ford, H. C., Crooke, M. J., and Murphy, C. E. (1989). Clin. Biochem. 22, 373–376.

    Article  PubMed  CAS  Google Scholar 

  35. Bambini, G., Aghini-Lombardi, F., Rosner, W., et al. (1987). Arch. Intern. Med. 147, 1781–1785.

    Article  PubMed  CAS  Google Scholar 

  36. Bilezikian, J. P. and Loeb, J. N. (1983). End. Rev. 4, 378–388.

    CAS  Google Scholar 

  37. Silva, J. E. (1995). Thyroid 5, 481–492.

    Article  PubMed  CAS  Google Scholar 

  38. Bang, P., Eriksson, U., Sara, V., Wivall, I.-L., and Hall, K. (1991). Acta Endocrinol. 124, 620–629.

    PubMed  CAS  Google Scholar 

  39. Póvoa, G., Roovete, A., and Hall, K. (1984). Acta Endocrinol. 107, 563–570.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karolinska Institute, Department of Medicine, Section of Endocrinology, Stockholm Söder Hospital, 118 83, Stockholm, Sweden

    Sven Röjdmark

  2. Department of Endocrinology and Diabetology, Karolinska Institute, Karolinska University Hospital, Stockholm

    Jan Calissendorff & Kerstin Brismar

  3. Department of Clinical Chemistry, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Olle Danielsson

Authors
  1. Sven Röjdmark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Calissendorff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olle Danielsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kerstin Brismar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Röjdmark.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Röjdmark, S., Calissendorff, J., Danielsson, O. et al. Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocr 27, 55–61 (2005). https://doi.org/10.1385/ENDO:27:1:055

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/ENDO:27:1:055

Key Words

Search

Navigation